Author Correction: Inflammation across tissues: can shared cell biology help design smarter trials? (Nature Reviews Rheumatology, (2023), 19, 10, (666-674), 10.1038/s41584-023-01007-2)
Hosack T., Thomas T., Ravindran R., Uhlig HH., Travis SPL., Buckley CD.
Correction to: Nature Review Rheumatology, published online 4 September 2023. In the version of the article initially published, there were errors in Fig. 1b. The boxes for IL-23 under “Axial spondyloarthritis” and for CTLA-4 under “Psoriasis” were mistakenly shown with the color signifying “effective” instead of “ineffective”, and the boxes for JAK under “Psoriatic arthritis” and “Psoriasis” were shown as “ineffective” instead of “effective”. Additionally, in the “Common and distinct therapeutic themes in IMIDs” section of the text, in the sentence now reading “Anti-IL-17A therapy is efficacious for patients with AS or PsA but deleterious for patients with Crohn’s disease”, “RA” appeared rather than “AS”. These errors have been corrected in the HTML and PDF versions of the article.